MICROBIOTA, IMMUNE SYSTEM AND COLORECTAL CANCER
https://doi.org/10.17650/2220-3478-2017-7-4-11-19
Abstract
The article briefly considers physiological aspects of the human gut microbiota, associations between dysbiosis and colorectal cancer (CRC), disturbance of immune system in CRC, mechanisms of avoidance of immune surveillance by tumors, genetic instability in CRC, collisions and perspective of immunotherapy of CRC.
About the Authors
E. P. Kharchenko
I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences
Russian Federation
Russian Federation
44 Toreza Prospekt, Saint Petersburg 194223
I. A. Solov’ev
S.M. Kirov Military Medical Academy, Ministry of Defense of Russia
Russian Federation
Russian Federation
6 Akademika Lebedeva St., Saint Petersburg 194044
References
1. De Rosa M., Rega D., Costabile V. et al. The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care. Ther Adv Gastroenterol 2016;9(6):861–86. DOI: 10.1177/1756283X16659790.
2. Харченко E.П. Канцерогенез: иммунная система и иммунотерапия. Иммунология 2011;32(1):50–6. [Kharchenko E.P. Carcinogenesis: the immune system and immunotherapy. Immunologiya = Immunology 2011;32(1):50–6. (In Russ.)].
3. Irrazábal T., Belcheva A., Girardin S.E. et al. The multifaceted role of the intestinal microbiota in colon cancer. Molecular Cell 2014;54(2):309–20. DOI: 10.1016/j.molcel.2014.03.039.
4. Makkouk A., Weiner G.J. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res 2014;75(1):5–10. DOI: 10.1158/0008-5472.CAN-14-2538.
5. Ha C., Lam Y.Y., Holmes A.J. Mechanistic links between gut microbial community dynamics, microbial functions and metabolic health. World J Gastroenterol 2014;20(44):16498–517. DOI: 10.3748/wjg.v20.i44.16498.
6. Pflughoeft K.J., Versalovic J. Human microbiome in health and disease. Annu Rev Pathol 2012;7:99–122. DOI: 10.1146/annurev-pathol-011811-132421.
7. McDermott A.J., Huffnagle G.B. The microbiome and regulation of mucosal immunity. Immunology 2013;142(1):24–31. DOI: 10.1111/imm.12231.
8. Jandhyala S.M., Talukdar R., Subramanyam C. et al. Role of the normal gut microbiota World J Gastroenterol 2015;21(29):8787–803. DOI: 10.3748/wjg.v21.i29.8787.
9. Dzutsev A., Goldszmid R.S., Viaud S. et al. The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. Eur J Immunol 2015;45(1):17–31. DOI: 10.1002/eji.201444972.
10. Cadwell K. The virome in host health and disease. Immunity 2015;42(5):805–13. DOI: 10.1016/j.immuni.2015.05.003.
11. Gagnière J., Raisch J., Veziant J. et al. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol 2016;22(2):501–18. DOI: 10.3748/wjg.v22.i2.501.
12. Tojo R., Suárez A., Clemente M.G. et al. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J Gastroenterol 2014;20(41):15163–76. DOI: 10.3748/wjg.v20.i41.15163.
13. Bäumler A.J., Sperandio V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature 2016;535(7610):85–93. DOI: 10.1038/nature18849.
14. Eloe-Fadrosh E.A., Rasko D.A. The human microbiome: from symbiosis to pathogenesis. Annu Rev Med 2013;64:145–63. DOI: 10.1146/annurev-med-010312-133513.
15. Forbes J.D., Van Domselaar G., Bernstein C.N. The gut microbiota in immunemediated inflammatory diseases. Front Microbiol 2016;7:1081. DOI: 10.3389/fmicb.2016.01081.
16. Peterson C.T., Sharma V., Elmén L., Peterson S.N. Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota. Clin Exp Immunol 2014;179(3):363–77. DOI: 10.1111/cei.12474.
17. Muszer M., Noszczyńska M., Kasperkiewicz K. et al. Human microbiome: when a friend becomes an enemy. Arch Immunol Ther Exp 2015;63(4):287–98. DOI: 10.1007/s00005-015-0332-3.
18. Fardini Y., Wang X., Temoin S. et al. Fusobacterium nucleatum adhesin FadA binds vascular endothelial cadherin and alters endothelial integrity. Mol Microbiol 2011;82(6):1468–80. DOI: 10.1111/j.1365-2958.2011.07905.x.
19. Rubinstein M.R., Wang X., Liu W. et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/b-catenin signaling via its FadA adhesin. Cell Host Microbe 2013;14(2):195–206. DOI: 10.1016/j.chom.2013.07.012.
20. Wu S., Morin P.J., Maouyo D. et al. Bacteroides fragilis enterotoxin induces c-Myc expression and cellular proliferation. Gastroenterology 2003;124(2):392–400. DOI: 10.1053/gast.2003.50047.
21. Lundberg J.O., Weitzberg E., Cole J.A. et al. Nitrate, bacteria and human health. Nat Rev Microbiol 2004;2(7):593–602. DOI: 10.1038/nrmicro929.
22. Sobko T., Huang L., Midtvedt T. et al. Generation of NO by probiotic bacteria in the gastrointestinal tract. Free Radic Biol Med 2006;41(6):985–91. DOI: 10.1016/j.freeradbiomed.2006.06.020.
23. Huycke M.M., Moore D.R. In vivo production of hydroxyl radical by Enterococcus faecalis colonizing the intestinal tract using aromatic hydroxylation. Free Radic Biol Med 2002;33(6):818–26.
24. Arthur J.C., Perez-Chanona E., Muhlbauer M. et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012;338(6103):120–3. DOI: 10.1126/science.1224820.
25. Carman R.J., van Tassell R.L., Kingston D.G. et al. Conversion of IQ, a dietary pyrolysis carcinogen to a direct-acting mutagen by normal intestinal bacteria of humans. Mutat Res 1988;206(3):335–42.
26. De Kok T.M., van Maanen J.M., Lankelma J. et al. Electron spin resonance spectroscopy of oxygen radicals generated by synthetic fecapentaene-12 and reduction of fecapentaene mutagenicity to Salmonella typhimurium by hydroxyl radical scavenging. Carcinogenesis 1992;13(7):1249–55. PMID: 1322251.
27. Salaspuro M. Bacteriocolonic pathway for ethanol oxidation: characteristics and implications. Ann Med 1996;28(3):195–200. PMID: 8811162.
28. Choi S.W., Mason J.B. Folate status: effects on pathways of colorectal carcinogenesis. J Nutr 2002;132(8 suppl):2413S–8S. PMID: 12163703.
29. Deplancke B., Finster K., Graham W.V. et al. Gastrointestinal and microbial responses to sulfate supplemented drinking water in mice. Exp Biol Med (Maywood) 2003;228(4):424–33. PMID: 12671187.
30. Christl S.U., Scheppach W., Kasper H. Hydrogen metabolism in the large intestine – physiology and clinical implications. Z Gastroenterol 1995;33(7):408–13. PMID: 7571760.
31. Gill C.I., Rowland I.R. Diet and cancer: assessing the risk. Br J Nutr 2002;88(suppl 1): S73–87. DOI: 10.1079/BJN2002632.
32. Hague A., Manning A.M., Hanlon K.A. et al. Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: implications for the possible role of dietary fibre in the prevention of large-bowel cancer. Int J Cancer 1993;55(3):498–505. PMID: 8397167.
33. Caderni G., De Filippo C., Luceri et al. Effects of black tea, green tea and wine extracts on intestinal carcinogenesis induced by azoxymethane in F344 rats. Carcinogenesis 2000;21(11):1965–9. PMID: 11062155.
34. Yamamoto M., Matsumoto S. Gut microbiota and colorectal cancer. Genes Environ 2016;38:11. DOI: 10.1186/s41021-016-0038-8.
35. Formica V., Cereda V., Nardecchia A. et al. Immune reaction and colorectal cancer: friends or foes? World J Gastroenterol 2014;20(35):12407–19. DOI: 10.3748/wjg.v20.i35.12407.
36. Pernot S., Terme M., Voron T. et al. Colorectal cancer and immunity: what we know and perspectives. World J Gastroenterol 2014;20(14):3738–50. DOI: 10.3748/wjg.v20.i14.3738.
37. De Vries N.L., Swets M., Vahrmeijer A.L. et al. The immunogenicity of colorectal cancer in relation to tumor development and treatment. Int J Mol Sci 2016;17(7):1030. DOI:10.3390/ijms17071030.
38. Mármol I., Sánchez-de-Diego C., Pradilla Dieste A. et al. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int J Mol Sci 2017;18(1):E197. DOI: 10.3390/ijms18010197.
39. Ballester V., Rashtak S., Boardman L. Clinical and molecular features of youngonset colorectal cancer. World J Gastroenterol 2016;22(5):1736–44. DOI: 10.3748/wjg.v22.i5.1736.
40. Rodriguez-Salasa N., Dominguezb G., Barderasc R. et al. Clinical relevance of colorectal cancer molecular subtypes. Crit Rev Oncol Hematol 2017;109:9–19. DOI: 10.1016/j.critrevonc.2016.11.007.
41. Aghagolzadeh P., Radpour R. New trends in molecular and cellular biomarker discovery for colorectal cancer. World J Gastroenterol 2016;22(25):5678–93. DOI: 10.3748/wjg.v22.i25.5678.
42. Patel A., Tripathi G., Gopalakrishnan K. Field cancerisation in colorectal cancer: a new frontier or pastures past? World J Gastroenterol 2015;21(13):3763–72. DOI: 10.3748/wjg.v21.i13.3763.
43. Podlaha O., Riester M., De S., Michor F. Evolution of the cancer genome. Trends Genet 2012;28(4):155–63. DOI: 10.1016/j.tig.2012.01.003.
44. Joyce J.A., Fearon D.T. T-cell exclusion, immune privilege, and the tumor microenvironment. Science 2015;348(6230): 74–80. DOI: 10.1126/science.aaa6204.
45. Palucka A.K., Coussens L.M. The basis of oncoimmunology. Cell 2016;164(6): 1233–47. DOI: 10.1016/j.cell.2016.01.049.
46. Харченко E.П. Иммунное узнавание и иммунная привилегия. Иммунология 2008;29(2):118–24. [Kharchenko E.P. Immune recognition and immune privilege. Immunologiya = Immunology 2008;29(2):118–24. (In Russ.)].
47. Харченко Е.П. Иммунная привилегия: патологический aспект. Иммунология 2009;30(4):249–55. [Kharchenko E.P. Immune privilege: a pathological aspect. Immunologiya = Immunology 2009;30(4):249–55. (In Russ.)].
48. Suntsova M., Garazha A., Ivanova A. et al. Molecular functions of human endogenous retroviruses in health and disease. Cell Mol Life Sci 2015;72(19):3653–75. DOI: 10.1007/s00018-015-1947-6.
49. Philippe P., Mullins C.S., Naville M. et al. Expression of young HERV-H loci in the course of colorectal carcinoma and correlation with molecular subtypes. Oncotarget 2015;6(37):40095–50111. DOI: 10.18632/oncotarget.5539.
50. Díaz-Carballo D., Acikelli A.H., Klein J. et al. Therapeutic potential of antiviral drugs targeting chemorefractory colorectal adenocarcinoma cells overexpressing endogenous retroviral elements. J Exp Clin Cancer Res 2015;34:81. DOI 10.1186/s13046-015-0199-5.
51. Harrison M.M., Jenkins B.V., O’ConnorGiles K.M. et al. A CRISPR view of development. Genes Dev 2016;28(17): 1859–72. DOI: 10.1101/gad.248252.114.
Review
Views:
808
Email this article 